INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of SteadyMed Ltd. -- STDY

NEW YORK--()--Levi & Korsinsky announces it has commenced an investigation of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQ:STDY) concerning possible violations of federal securities laws.

On August 31, 2017, SteadyMed revealed that it received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") regarding it New Drug Application ("NDA") for its product candidate Treyvent. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review. To obtain additional information, go to:

http://www.zlkdocs.com/STDY-Info-Request-Form-6069

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky reminds investors it has commenced an investigation of SteadyMed Ltd.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com